MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
29.48
-0.46
-1.54%
Closed 19:30 11/12 EST
OPEN
29.20
PREV CLOSE
29.94
HIGH
29.78
LOW
28.59
VOLUME
1.92M
TURNOVER
--
52 WEEK HIGH
32.21
52 WEEK LOW
12.00
MARKET CAP
4.77B
P/E (TTM)
-65.3659
1D
5D
1M
3M
1Y
5Y
1D
Adaptive Biotechnologies (ADPT) Lands In $17.1 Billion DNA Sequencing Market Report
Simply Wall St · 19h ago
Adaptive Biotechnologies price target raised to $35 from $27 at Piper Sandler
TipRanks · 2d ago
Adaptive Biotechnologies Is Maintained at Buy by Guggenheim
Dow Jones · 2d ago
Adaptive Biotechnologies Price Target Raised to $34.00/Share From $32.00 by Guggenheim
Dow Jones · 2d ago
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34
Benzinga · 2d ago
Analysts Offer Insights on Healthcare Companies: Zura Bio (ZURA), Adaptive Biotechnologies (ADPT) and Editas Medicine (EDIT)
TipRanks · 2d ago
Adaptive Biotechnologies (ADPT) Stock Looks Reasonable As Cash Flow Recovery Takes Shape
Simply Wall St · 2d ago
Adaptive Biotechnologies price target raised to $35 from $30 at JPMorgan
TipRanks · 3d ago
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.